statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

India VIX has more room to rise and the volatility could continue until the general election results are announced, say analysts

Sensex, Nifty turn green, fully recover from 1% intraday fall; analysts say 'exercise caution'

Cipla plans to launch 12 assets in peptides and complex generics space and 5 in the respiratory segment over FY25-27, which brokerages believe will secure its growth path for the next 3-4 years.

Cipla's strong US pipeline, steady Q4 earnings and hopes of easing regulatory snags drive bullishness

Currently Cipla has the right to sell, promote and distribute two diabetes drugs of Eli Lilly in India

Open to market Eli Lilly’s weight loss drugs in India: Cipla CEO

A Moneycontrol poll of eight brokerages pegged the net profit at Rs 891  crore.

Cipla beats estimates as Q4 net profit zooms 78% to Rs 939 crore

Cipla's US sales likely to surge in Q4, driven by the contribution from Revlimid, along with a stable market share in Albuterol (respiratory drug) and an expansion in Lanreotide (hormonal drug) and Brovana (inhalation drug)

Cipla Q4 results preview: Revenue boost likely from strong US sales, net profit to jump from low base

The volatility index (VIX) bouncing back suggests challenges ahead, while on the downside, a breach below 22,300 could lead to a slide towards 22,100–22,000 on the Nifty.

Three stocks that can deliver up to 10% in the short term; watch out for the rising VIX

The Head of Institutional Equities at HDFC Securities expects consumption demand to witness a slight pickup in FY25 and suggests adding exposure to the FMCG sector on a selective basis.

Daily Voice | These 4 pharma stocks to benefit from change in 2 trends: HDFC Securities' Unmesh Sharma

Net Sales are expected to decrease by 4.7 percent Y-o-Y (up 9.6 percent Q-o-Q) to Rs 6,290.9 crore, according to ICICI Securities.

Cipla Q4 PAT may dip 24.9% YoY to Rs 869.4 cr: ICICI Securities

Breach of 22,500-22,450 levels may trigger further profit booking, potentially towards 22,300 and beyond in the near term.

Hot Stocks: Here's why it's prudent to buy CDSL and sell Cipla for the short term

After witnessing consistent double-digit growth in branded formulations business in recent years, growth in the domestic formulation segment has moderated to high single digits

Steady US sales to bring a healthy quarter for pharma sector

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Watchers	4,644
52-Wk Low	911.55
52-Wk High	1,519.00

Volume	2.53M
52-Wk High	1,519.00
52-Wk Low	911.55

CIPLA.NSE Cipla Ltd.

About

Feed

News

Sentiment

Fundamentals